Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.

Clinical trial NCT03983954 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT03983954
Sponsor: NeoTX Therapeutics Ltd.
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

ER+ Breast Cancer Ovarian Cancer Cervical Squamous Cell Carcinoma Pancreatic Adenocarcinoma Endometrial Cancer Renal Cell Carcinoma Urothelial Cancer Head and Neck Squamous Cell Carcinoma Mesothelioma Melanoma Hepatocellular Carcinoma Prostate Cancer

Start date: 2019-10-10
Primary completion: 2027-03-01
Enrollment: 120

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.